Biosensor for simultaneously detecting cell-free DNA and microrna using crispr-cas12a and crispr-cas13a
The CRISPR-based biosensor with gold nanorods and CRISPR-Cas enzymes addresses the limitations of existing technologies by enabling rapid and accurate multiplex detection of cfDNA and miRNA, enhancing cancer diagnosis through simultaneous detection of multiple biomarkers.
WO2026141850A1PCT designated stage Publication Date: 2026-07-02IND COOP FOUND CHONBUK NAT UNIV
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IND COOP FOUND CHONBUK NAT UNIV
- Filing Date
- 2025-09-08
- Publication Date
- 2026-07-02
Smart Images
Figure KR2025013851_02072026_PF_FP_ABST
Abstract
The present invention relates to: a biosensor for simultaneous multiplex detection of target nucleic acid molecules, the biosensor comprising gold nanorods with immobilized ssDNA and ssRNA; and a composition for diagnosing cancer using the biosensor. The present invention enables rapid simultaneous multiplex detection of cancer-associated cfDNA and miRNA, which are target nucleic acid molecules, to be performed with high accuracy and sensitivity, and thus can be advantageously used in the field of cancer diagnosis.
Need to check novelty before this filing date? Find Prior Art